Gray, J. C., Weston, R., Owens, C., Canete, A., Gambart, M., Wilde, B. D., Nysom, K., Eijkelenburg, N. V., Ladenstein, R., Castellano, A., Gerber, N. U., Marshall, L. V., Barone, G., Rubio-San-Simon, A., Ng, A., Vaidya, S., Gallego, S., Makin, G., Burke, G. A. A., McCarthy, A., Murphy, D., Zwaan, C. M., Lopez-Almaraz, R., Jannier, S., Thebaud, E., Corradini, N., Yeomanson, D., Howell, L., Tweddle, D. A., Elliott, M., Hobin, D., Valteau-Couanet, D., Schleiermacher, G., Chastagner, P., Defachelles, A. S., Brichard, B., George, S., Chesler, L., Laidler, J., Firth, C., Holt, G., Moroz, V., Pearson, A. D., Gates, S., Wheatley, K., Kearns, P., Moreno, L. (2026). Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-01868